Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease.

Han M, Park HC, Kim H, Jo HA, Huh H, Jang JY, Kang AY, Kim SH, Cheong HI, Kang DH, Yang J, Oh KH, Hwang YH, Ahn C.

BMC Nephrol. 2014 Apr 16;15:63. doi: 10.1186/1471-2369-15-63.

2.

Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease.

Kim Y, Shin S, Kim K, Choi S, Lee K.

J Rheumatol. 2015 Nov;42(11):2143-8. doi: 10.3899/jrheum.150067. Epub 2015 Oct 1.

PMID:
26428209
3.

Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.

Levy GD, Rashid N, Niu F, Cheetham TC.

J Rheumatol. 2014 May;41(5):955-62. doi: 10.3899/jrheum.131159. Epub 2014 Apr 1.

PMID:
24692523
4.

Uric acid: association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients.

Nacak H, van Diepen M, de Goeij MC, Rotmans JI, Dekker FW; PREPARE-2 study group.

BMC Nephrol. 2014 Jun 16;15:91. doi: 10.1186/1471-2369-15-91.

5.

Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease.

Panizo N, Goicoechea M, García de Vinuesa S, Arroyo D, Yuste C, Rincón A, Verdalles U, Ruiz-Caro C, Quiroga B, Luño J.

Nefrologia. 2012;32(2):197-205. doi: 10.3265/Nefrologia.pre2011.Dec.11177. Epub 2012 Jan 27. English, Spanish.

6.

Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate.

See LC, Kuo CF, Chuang FH, Li HY, Chen YM, Chen HW, Yu KH.

J Rheumatol. 2009 Aug;36(8):1691-8. doi: 10.3899/jrheum.081199. Epub 2009 Jun 16.

PMID:
19531754
7.

Serum uric acid and chronic kidney disease: the role of hypertension.

Sedaghat S, Hoorn EJ, van Rooij FJ, Hofman A, Franco OH, Witteman JC, Dehghan A.

PLoS One. 2013 Nov 12;8(11):e76827. doi: 10.1371/journal.pone.0076827. eCollection 2013.

8.

Association of uric acid and left ventricular mass index with renal outcomes in chronic kidney disease.

Chen SC, Chang JM, Yeh SM, Su HM, Chen HC.

Am J Hypertens. 2013 Feb;26(2):243-9. doi: 10.1093/ajh/hps020. Epub 2012 Dec 28.

PMID:
23382409
9.

Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease.

Choukroun G, Itakura Y, Albouze G, Christophe JL, Man NK, Grünfeld JP, Jungers P.

J Am Soc Nephrol. 1995 Dec;6(6):1634-42.

10.

Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM.

Nephrol Dial Transplant. 2013 Feb;28(2):380-5. doi: 10.1093/ndt/gfs417. Epub 2012 Dec 4.

11.

Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.

Rodenbach KE, Schneider MF, Furth SL, Moxey-Mims MM, Mitsnefes MM, Weaver DJ, Warady BA, Schwartz GJ.

Am J Kidney Dis. 2015 Dec;66(6):984-92. doi: 10.1053/j.ajkd.2015.06.015. Epub 2015 Jul 21.

12.

Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.

Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E.

Diabetes Care. 2012 Jan;35(1):99-104. doi: 10.2337/dc11-1346. Epub 2011 Oct 25.

13.

A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population.

Kamei K, Konta T, Hirayama A, Suzuki K, Ichikawa K, Fujimoto S, Iseki K, Moriyama T, Yamagata K, Tsuruya K, Kimura K, Narita I, Kondo M, Asahi K, Watanabe T.

Nephrol Dial Transplant. 2014 Dec;29(12):2286-92. doi: 10.1093/ndt/gfu256. Epub 2014 Jul 24.

PMID:
25061123
14.

Hyperuricemia associated with rapid renal function decline in elderly Taiwanese subjects.

Yen CJ, Chiang CK, Ho LC, Hsu SH, Hung KY, Wu KD, Tsai TJ.

J Formos Med Assoc. 2009 Dec;108(12):921-8. doi: 10.1016/S0929-6646(10)60004-6.

15.

Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.

Spithoven EM, Meijer E, Boertien WE, Sinkeler SJ, Tent H, de Jong PE, Navis G, Gansevoort RT.

Am J Kidney Dis. 2013 Sep;62(3):531-40. doi: 10.1053/j.ajkd.2013.03.030. Epub 2013 May 25.

PMID:
23714171
16.

The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre.

Thong KM, Ong AC.

QJM. 2013 Jul;106(7):639-46. doi: 10.1093/qjmed/hct082. Epub 2013 Apr 15.

PMID:
23587574
17.

Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.

Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT, Klahr S, Bennett WM, Meyers CM, Thompson PA, Miller JP; CRISP Consortium.

J Am Soc Nephrol. 2006 Mar;17(3):854-62. Epub 2006 Feb 1.

18.

Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.

Perkins RM, Kirchner HL, Hartle JE, Bucaloiu ID.

Clin Nephrol. 2013 Oct;80(4):256-62. doi: 10.5414/CN107905.

PMID:
23993165
19.

Renal disease progression in autosomal dominant polycystic kidney disease.

Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K.

Clin Exp Nephrol. 2012 Aug;16(4):622-8. doi: 10.1007/s10157-012-0611-9. Epub 2012 Apr 21.

20.

Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider.

Neri L, Rocca Rey LA, Lentine KL, Hinyard LJ, Pinsky B, Xiao H, Dukes J, Schnitzler MA.

Am J Kidney Dis. 2011 Sep;58(3):398-408. doi: 10.1053/j.ajkd.2011.04.025. Epub 2011 Jul 23.

PMID:
21783292

Supplemental Content

Support Center